Diabetes: managing dyslipidaemia

source extracted confidence: high 2026-04-09
#cardiovascular-diseases #diabetes-mellitus-type-2 #dyslipidemias #humans #hydroxymethylglutaryl-coa-reductase-inhibitors

Diabetes: managing dyslipidaemia

Patel et al., 2008 | BMJ Clin Evid | Systematic Review

Citation

Patel Jigisha. Diabetes: managing dyslipidaemia. BMJ Clin Evid. 2008-Jun-09;2008

Abstract

INTRODUCTION: Dyslipidaemia is a major contributor to the increased risk of heart disease found in people with diabetes. An increase of 1 mmol/L LDL-C is associated with a 1.57-fold increase in the risk of coronary heart disease (CHD) in people with type 2 diabetes. A diagnosis of diabetic dyslipidaemia requiring pharmacological treatment is determined by the person's lipid profile and level of cardiovascular risk. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of interventions for dyslipidaemia in people with diabetes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 21 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: anion exchange resins, combined treatments (for lipid modification), ezetimibe, fibrates, fish oil (for lipid modification), intensive multiple intervention treatment programmes (for lipid modification), nicotinic acid (for lipid modification), and statins.

Key Findings

We found 21 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition diabetes

MeSH Terms

  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Dyslipidemias
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Risk Factors

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Systematic Review
  • Vertical: niacin

Provenance

  • PMID: 19450295
  • DOI: (not available)
  • PMCID: PMC2907966
  • Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09